Pharmaceuticals

Renin-Angiotensin-System (RAS)-Acting Agents Industry Forecast to Hit $7.55 Billion by 2029 With a Strong 5.4% CAGR

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Renin-Angiotensin-System (RAS)-Acting Agents Market Size During 2025–2029?

The market size for renin-angiotensin-system (RAS)-acting agents has experienced consistent growth over recent years. This market is projected to expand from $5.82 billion in 2024 to $6.11 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 5.0%. Historically, this expansion has been driven by factors such as the rising occurrence of hypertension, the increasing frequency of cardiovascular diseases, an expanding aging demographic, heightened public awareness regarding blood pressure control, robust support from clinical research, and the successful regulatory approval of new medications.

The market for renin-angiotensin-system (RAS)-acting agents is projected to experience robust expansion over the coming years. This market is forecast to reach $7.55 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.4%. This projected growth during the forecast period is fueled by several factors, including an increased emphasis on personalized treatment, a surge in demand for fixed-dose drug combinations, greater investment in cardiovascular research, improved healthcare accessibility in developing economies, and the escalating incidence of lifestyle-associated illnesses. Key developments anticipated within this timeframe encompass artificial intelligence (AI)-powered drug development, drug delivery utilizing nanotechnology, strides in personalized medicine, the application of blockchain for securing clinical data, the use of wearable biosensors for blood pressure monitoring, and the implementation of digital twin technology for modeling patient scenarios.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What Are The Drivers Pushing New Developments In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The rising occurrence of hypertension is anticipated to boost the expansion of the renin-angiotensin system (RAS)-acting agents market. Hypertension, also known as elevated blood pressure, is a persistent medical state characterized by excessively high blood pressure against arterial walls. The increase in hypertension cases stems from poor dietary habits, specifically those rich in sodium and processed items, which lead to higher blood pressure and stress on the heart and blood vessels. Renin-angiotensin system (RAS)-acting agents aid in decreasing hypertension rates by managing blood pressure; they achieve this by blocking angiotensin II, a hormone that narrows blood vessels and causes fluid buildup, thus encouraging vessel widening and reducing blood pressure. As an illustration, data from October 2024 by the Australian Bureau of Statistics, an Australia-based government agency, indicated that 11.6% (3.0 million) of Australians suffered from hypertension in 2022, with comparable figures for males (11.7%) and females (11.6%). Consequently, the growing incidence of hypertension is fueling the growth of the renin-angiotensin system (RAS)-acting agents market.

Which Key Segments Fueling The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

Which Ongoing Trends Are Expected To Shape The Renin-Angiotensin-System (RAS)-Acting Agents Market Outlook?

Leading companies in the renin-angiotensin system (RAS)-acting agents market are concentrating on developing innovative renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors. This focus aims to boost efficacy, minimize adverse effects, enhance patient adherence, and address conditions including hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor is a medication that effectively lowers blood pressure by inhibiting the enzyme responsible for converting angiotensin I to angiotensin II, a substance known to constrict blood vessels. As an example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets. These tablets are indicated for treating heart failure in children from birth to less than 18 years. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, works to treat pediatric heart failure patients by blocking the angiotensin-converting enzyme (ACE). This prevents the conversion of angiotensin I to angiotensin II, consequently relaxing blood vessels, improving blood flow, and lessening the heart’s workload.

Which Major Industry Participants Are Leading The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

What Are The Key Regional Factors Influencing The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Renin-Angiotensin-System (RAS)-Acting Agents Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Wearable Blood Pressure Monitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wearable-blood-pressure-monitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795